Four biotechs hit Wall Street with up­sized IPOs, each rais­ing more than $20M over their goals

Four more biotechs have jumped on­to Nas­daq, each rais­ing over $20 mil­lion more than their ini­tial goals and adding to this year’s record-high to­tal raise of more than $14 bil­lion.

Seer, Sig­ilon Ther­a­peu­tics, Sil­ver­back Ther­a­peu­tics, and Kin­nate Bio­phar­ma raked in $175 mil­lion, $126 mil­lion, $241.5 mil­lion and $240 mil­lion re­spec­tive­ly.

Seer priced its up­sized of­fer­ing of 9.2 mil­lion shares at $19 apiece, above a $16 to $18 range it set ear­li­er this week. The Red­wood City, CA-based biotech ini­tial­ly set out for a $150 mil­lion raise. It was launched by CEO Omid Farokhzad, who left his gig in a nano-med­i­cine lab at Boston’s Brigham and Women’s Hos­pi­tal about two years ago to build a com­pa­ny around tech­nol­o­gy he said would change the field of pro­teomics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.